mAb Capture Made Cost Effective and Productive With Cytiva’s Protein A Resins

A one-size-fits-all strategy to protein purification is no longer practicable, given the development and transformation of the mAb market, notably the recent rapid emergence of biosimilars. To solve this, Cytiva created two new protein A resins, the MabSelect SuRe 70 and the MabSelect PrismA X.

Advertisement

The different stages of drug development require different purification needs. As more molecules are being brought to clinic, we wanted to provide our customers with innovative and cost-effective options regardless of stage. These new resins offer affordability without sacrificing quality.

Sofie Stille

Cytiva has expanded its entire protein A resin portfolio with three new resins, providing clients with additional alternatives to lower manufacturing costs and boost flexibility while keeping the high-quality standards they expect.

The necessity for cost is especially important at the purification stage of preclinical or clinical manufacture, where no more than 20 batches are conducted. Meanwhile, in commercial production, speed and performance are critical.

Also Read: Monoclonal Antibodies – Definition, Structure and Working

Advertisement

At whatever stage or scale a customer is at, we can offer solutions that fit based on speed, performance, or affordability, each sustainably designed.

Sofie Stille

MabSelect resins are based on agarose, a renewable raw material that aligns with Cytiva’s environmental goals. Since 2022, Cytiva has owned its agarose manufacturing and processing facilities in Denmark, which is near to the Swedish resins manufacturing site. Cytiva has also taken steps to strengthen its supply chain security by opening a second production site in North America. The Muskegon, Michigan location has been completely renovated and is on pace for technology transfer.

Also Read:  Creating an antibody to prevent muscular atrophy brought on by aging

Source: Cytiva


Last Modified:

Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.

Advertisement

Ajmal Aseem

Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.

Next Post

Dire Wolf Returns After 12000 Years By De-Extinction Technology

Wed Apr 9 , 2025
Written by Ajmal Aseem | Reviewed by Editor's Desk Colossal Biosciences, the business seeking to make extinction optional, has resurrected a prehistoric predator best known for its role in Game of Thrones. Approximately 20 distinctive genetic variations related to distinct dire wolf features were discovered. These characteristics include greater stature, a more […]
dire wolf

Related Articles